XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

NCT05927844 | Unknown Phase 1 DMC

• 1 other identifier: SCOG007
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in the treatment of locally advanced or metastatic esophageal squamous cell carcinoma.

Conditions

Esophageal Squamous Cell Carcinoma

Outcome Measures

Primary Outcomes (2)

• Incidence of Treatment-Related Adverse Events and SAE

  The Treatment-Related Adverse Events and SAE will be assessed by CTCAE5.0.

  through study completion, an average of 6 months

• severity of TEAE and SAE

  The Treatment-Related Adverse Events and SAE will be assessed by CTCAE5.0.

  through study completion, an average of 6 months

Study Arms (2)

Treatment ARM1

EXPERIMENTAL

Drugs1：XH30002 Capsual 300mg，Qd，28d; Drug2：Afatiinb tablets 30mg，Qd，28d

Drug: XH-30002 capsule; Drug: Afatiinb tablet

Treatment ARM2

EXPERIMENTAL

Drugs1：XH30002 Capsual 400mg，Qd，28d; Drug2：Afatiinb tablets 30mg，Qd，28d

Drug: XH-30002 capsule; Drug: Afatiinb tablet

Interventions

XH-30002 capsule DRUG

receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first

Treatment ARM1; Treatment ARM2

Afatiinb tablet DRUG

receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first

Treatment ARM1; Treatment ARM2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily participate in the study, agree to complete the corresponding visit and inspection according to the research plan, and sign the informed consent form (ICF);
• Age ≥18 years old (as of the date of signing the ICF);
• Esophageal squamous cell carcinoma confirmed by histology or cytology;
• Patients with disease progression or intolerance after receiving at least first-line systemic treatment or refusing to accept standard treatment for various reasons;
• The physical status score of the Eastern United States Oncology Consortium (ECOG) was 0-2;
• Presence of at least one evaluable lesion according to RECIST 1.1 evaluation criteria;
• Within 7 days before the first dose, the function of major organs and bone marrow meets the following criteria (in cases where blood transfusion or hematopoietic stimulation is not corrected within 14 days before the test) :
• Neutrophil count ≥1.5×109/L;
• Platelet count ≥100×109/L;
• Hemoglobin ≥90g/L;
• Liver function: For subjects with total bilirubin (TBIL) ≤1.5× upper reference value (ULN) or TBIL\>1.5×ULN, direct bilirubin ≤1.0×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (liver metastasis subjects ≤5×ULN); Albumin ≥3.0g/dL;
• Renal function: serum creatinine ≤1.5×ULN or creatinine clearance ≥50mL/min (calculated by Cockcroft-Gault formula);
• Coagulation function: International standardized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5×ULN;
• Expected survival time ≥3 months;
• Women of reproductive age must undergo a negative blood pregnancy test within 7 days prior to enrollment and agree to use a reliable and effective method of contraception during the study treatment period and for 6 months after the last study treatment; For male subjects whose partner is a woman of reproductive age, consent must be given to use a reliable and effective method of contraception during the study treatment period and for 6 months after the last study treatment (whichever is the longest).

You may not qualify if:

• Past or current use of afatinib maleate tablets or anti-tumor drugs targeting CDK4/6;
• the presence of other active malignancies within 3 years prior to the first dose, except for locally curable tumors that have already received radical treatment (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, breast carcinoma in situ, early thyroid cancer, etc.);
• Within 7 days before the first dose, there is uncontrollable serosal effusion requiring frequent drainage or medical intervention (such as pleural effusion, abdominal effusion, pericardial effusion, etc.);
• Patients with central nervous system metastases (except asymptomatic brain metastases);
• The toxicity level of previous anti-tumor therapy has not been restored to the General Adverse Event Term Standard 5.0 (CTCAE5.0) ≤ grade 1 (alopecia, peripheral neurotoxicity, simple laboratory tests and other toxicity that researchers judge no safety risk need to be mitigated to ≤ grade 2);
• Those who have used potent inhibitors or inducers of CYP3A4 or CYP2C8 within 14 days before the first dose;
• A history of hypersensitivity to any investigational drug ingredient or any known excipient
• Patients with uncontrolled or significant cardiovascular and cerebrovascular diseases, including but not limited to:
• New York Heart Association (NYHA) Class II or higher congestive heart failure, unstable angina pectoris, myocardial infarction, or arrhythmia causing hemodynamic instability in the six months prior to screening;
• primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restricted cardiomyopathy, undefined cardiomyopathy);
• a history of clinically significant QT interval prolongation, or a screening period QTcF (calculated using Fridericia's formula) \> 450 ms; Left ventricular ejection fraction (LVEF) ≤50%;
• Occurrence of arterial/venous thrombosis events, such as cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc. within 6 months before screening;
• Uncontrolled hypertension after optimal treatment (systolic blood pressure \> 160mmHg or diastolic blood pressure \> 100mmHg);
• Esophagotracheal fistula, esophagomediastinal fistula, or tumor invasion risk of surrounding large blood vessels were diagnosed by imaging examination;
• Gastrointestinal obstruction and active inflammatory bowel disease within 28 days prior to initial administration; The presence of chronic gastrointestinal dysfunction with diarrhea as the main symptom or other gastrointestinal disorders determined by investigators to be clinically significant, such as Crohn's disease, ulcerative colitis, malabsorption, or grade 1 diarrhea;

Sponsors & Collaborators

• Fujian Cancer Hospital: lead

MeSH Terms

Conditions

Esophageal Squamous Cell Carcinoma

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell; Esophageal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Study Officials

• Gen Lin, Ph.D

  Fujian Cancer Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gen Lin, Ph.D

CONTACT

+86-13313786157; fjzllg133@fjzlhospital.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Masking Details: Open Label
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Model Details: open, single-arm

Study Record Dates

• First Submitted: June 14, 2023
• First Posted: July 3, 2023
• Study Start: June 1, 2023
• Primary Completion: June 1, 2025
• Study Completion: June 1, 2025
• Last Updated: July 3, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share